Skip to main content

Table 1 Patient demographic and clinical characteristics in the QUEST-RA Study by country

From: Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA Study

Country

Sites

Patients

Female, percentage

Age, years

Disease duration, years

DMARD delay, months

RF+, percentage

Smoking now, percentage

DAS28

SJC28

ESR

Pain

Patient global

HAQ

Taking now, percentage

               

Pred

MTX

Any biologic

Netherlands

3

317

66.3

59.2

9.2

6.0

68.8

22.9

3.1

1.0

15.0

2.5

2.7

0.8

16.1

74.1

19.6

Finland

3

304

72.4

58.5

13.5

7.0

74.8

15.5

3.3

1.0

13.0

2.8

2.8

0.6

51.3

61.5

12.5

USA

3

301

72.9

57.5

9.3

9.0

70.9

20.5

3.3

2.0

14.0

3.2

2.6

0.6

60.1

71.8

27.6

Greece

3

300

75.7

58.1

11.8

7.0

52.1

15.8

3.4

0.0

23.0

2.3

2.0

0.3

70.7

71.3

47.0

Denmark

3

301

76.7

57.8

12.0

11.0

73.3

31.6

3.4

1.0

14.0

2.6

2.8

0.6

14.6

71.1

21.3

Spain

3

302

73.5

59.8

10.6

14.0

72.5

17.8

3.5

1.0

17.0

3.1

3.6

0.9

46.7

56.3

23.2

France

4

389

77.9

55.3

12.8

8.0

75.3

19.1

3.7

1.0

16.0

3.9

3.6

0.9

60.9

57.1

44.2

Sweden

3

260

71.8

59.4

12.5

12.0

81.6

19.2

3.8

2.0

19.0

3.3

3.3

0.9

41.2

65.8

26.9

UK

3

145

77.9

59.6

15.0

16.0

81.4

19.4

4.0

1.0

19.0

4.1

3.6

0.9

28.3

70.3

14.5

Ireland

3

240

64.3

56.4

11.3

11.0

79.6

24.6

4.1

3.0

18.0

3.4

2.9

0.8

31.7

71.7

32.1

Canada

1

100

78.8

57.9

12.4

11.0

82.8

30.0

4.1

2.0

21.0

4.6

4.0

1.0

25.0

49.0

23.0

Turkey

3

309

85.6

52.2

11.6

12.0

67.6

14.1

4.2

0.0

30.0

4.2

4.6

0.9

57.3

69.3

5.8

Brazil

3

115

88.6

52.3

8.5

8.0

79.6

13.3

4.2

3.0

28.0

3.2

3.5

0.6

53.9

80.0

25.2

UAE

2

199

85.8

45.3

6.4

11.7

75.4

6.3

4.3

3.0

23.5

3.7

2.8

0.6

35.2

53.3

7.5

Germany

3

225

83.6

58.8

13.4

15.0

60.9

13.5

4.4

3.0

20.0

5.0

4.9

0.8

26.7

45.8

22.7

Italy

4

336

78.2

61.0

10.5

9.0

71.4

15.9

4.5

2.0

28.0

4.9

5.0

1.0

51.8

53.3

12.5

Estonia

3

168

85.5

55.8

11.8

12.0

68.1

14.0

4.7

4.0

24.0

4.3

4.8

1.1

43.5

53.6

0.6

Russia

3

73

84.5

54.2

6.2

10.0

74.6

15.4

5.0

5.0

24.0

3.6

4.5

1.1

38.4

46.6

16.4

Hungary

3

153

87.4

57.9

12.6

12.0

92.8

25.3

5.1

5.0

26.0

5.2

5.1

1.4

36.6

62.7

12.4

Latvia

1

79

79.7

53.2

13.2

32.1

84.6

19.2

5.2

4.0

26.0

5.1

5.7

1.4

63.3

70.9

21.5

Poland

7

642

86.7

53.2

11.5

4.0

70.3

11.9

5.3

6.0

31.0

5.0

4.8

1.4

58.9

65.0

6.1

Argentina

2

246

90.2

51.4

9.9

13.0

90.5

21.4

5.3

9.0

30.0

5.0

4.7

1.0

63.4

48.8

2.8

Lithuania

2

300

82.9

54.1

10.7

15.0

78.4

7.1

5.5

3.0

29.0

5.2

5.3

1.4

82.7

55.7

9.3

Serbia

1

100

88.0

59.2

10.1

11.1

71.4

18.4

5.9

6.0

28.0

5.1

5.3

1.6

54.0

54.0

0.0

Kosovo

1

100

84.0

55.0

7.8

3.0

80.6

10.4

6.0

6.0

45.0

5.1

5.0

1.6

90.0

71.0

1.0

Total

70

6,004

79.2

56.2

11.2

10.0

73.6

17.4

4.2

2.0

22.0

4.1

4.2

0.9

49.1

62.5

18.3

  1. Mean values are presented for age, disease duration, and disease activity score using 28 joint counts (DAS28). Median values are presented for other continuous variables. DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MTX, methotrexate; Pred, prednisone; QUEST-RA, Quantitative Standard Monitoring of Rheumatoid Arthritis; RF, rheumatoid factor; SJC, swollen joint count; UAE, United Arab Emirates.